We evaluated the effect of pretreatment with nitric oxide precursor before ischemia on recovery with reperfusion in rat hearts. Methods: Isolated rat hearts were perfused with Krebs-Henseleit buffer without (C group) or with 3 mmol/L L-arginine (A group) before 30 minutes of ischemia. The left ventricular function, including heart rate, developed pressure, maximal dp/dt, and coronary flow, were measured before pretreatment and after 10 and 30 minutes of reperfusion. Cyclic guanosine monophosphate (by radioimmunoassay), calcium (by absorption spectrophotometry), and inositol 1,4,5-triphosphate synthesized from tritiated myo-inositol (by ion-exchange chromatography preceding counting) were measured at the same times and immediately after ischemia. 
N itric oxide (NO), an endothelially derived, smooth muscle-relaxing factor, is well known as a physiologically important vasodilator. Recent papers have suggested that NO also is a regulator of cell metabolism, which can reduce adenosine triphosphate (ATP) by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and mitochondrial function 1 and cause cell injury by production of peroxynitrite. 2, 3 Previous studies have demonstrated that NO increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells by activation of soluble guanylate cyclase (sGC). 4 Other investigators have reported that cGMP decreases the cytosolic Ca 2ϩ content, or [Ca 2ϩ ]i through several mechanisms, including inhibition of the phosphatidylinositol pathway, 5, 6 indirect inhibition of Ca 2ϩ channels, 7 and stimulation of plasma membrane Ca 2ϩ pumps. 8, 9 In addition, some studies have linked the cardioprotective effects of NO in ischemia-reperfused hearts to attenuation of neutrophil accumulation and adhesion, [10] [11] [12] [13] [14] [15] [16] inhibition of superoxide anion production, [17] [18] [19] and protection of coronary endothelial cell function. 11, 20 An NO precursor as a pretreatment or an addition to a cardioplegic solution is an appealing prospect in cardiac surgery, provided it is safe. We explored mechanisms of cardioprotection by such pretreatment in isolated rat hearts.
Methods
The investigation was performed in accordance with the guidelines in the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication No 85-23, revised 1985).
Experimental preparation. Male Sprague-Dawley rats (body weight 250 to 300 gm) were anesthetized by intraperitoneal injection of pentobarbital (80 mg/kg) and heparinized (200 units via the femoral vein). After thoracotomy, their hearts were rapidly excised and arrested in cold-modified Krebs-Henseleit bicarbonate buffer solution (mKHB buffer: NaCl, 118 mEq/L; KCl, 4.7 mEq/L; KHPO 4 , 1.2 mEq/L; NaHCO 3 , 24 mEq/L; MgSO 4 , 1.2 mEq/L; glucose, 10 mEq/L; CaCl 2 , 1.7 mEq/L; gassed with 95% oxygen and 5% carbon dioxide, pH 7.4). The ascending aorta was cannulated and hearts were perfused in the nonrecirculating Langendorff mode with mKHB buffer at 37°C at a pressure of 100 cm H 2 O for 10 minutes. Myocardial temperature was maintained at 37°C by a surrounding water jacket.
Experimental protocol. The experimental protocol is represented as a time line in Fig. 1 . After an initial 10-minute perfusion, hearts were perfused another 10 minutes with mKHB buffer (C group) or with mKHB buffer containing 3 mmol/L L-arginine (A group, Sigma Chemical Co., St. Louis, Mo.). The hearts were then subjected to 30 minutes of normothermic global ischemia, after which they were perfused with mKHB buffer at 37°C for 30 minutes. Modified KHB buffer was gassed with 95% oxygen and 5% carbon dioxide during the experiments, and oxygen tension of mKHB was kept higher than 600 mm Hg after reperfusion. Contractile functions were obtained at baseline before the first perfusion (Base) and after 10 (R10) and 30 minutes (R30) of reperfusion. Tissue samples for the measurement of cGMP, inositol phosphates, and calcium content were obtained each time from the separate rats, which were perfused and reperfused on the same protocol. Rats were randomly assigned to the treatment group and the resected tissue samples of each time. Total number of the hearts was 96.
Myocardial contractile function. Aspects of left ventricular function evaluated included heart rate (beats/ min), maximum developed pressure (dp max, mm Hg), the first derivative of the left ventricular pressure (LV dp/dt max, mm Hg/sec), and coronary blood flow. Pressures were measured with a fluid-filled compliant balloon (0.5 ml) that was connected by fluid-filled polyethylene tubing to a pressure transducer (P23ID; Gould, Inc., Cleveland, Ohio). The balloon was inserted into the left ventricle through the mitral valve. Developed pressure was measured as the difference between peak systolic pressure and end-diastolic pressure. Coronary flow (ml/ min) was assessed by measuring the volume of coronary effluent ones (n ϭ 12; six rats were used in each group. These 12 hearts were also used as the samples of intracellular Ca 2ϩ concentration and cGMP after 30 minutes of reperfusion.) Intracellular calcium concentration. After left ventricular function was measured and also after ischemia, transmural tissue specimens were obtained from the left ventricular wall. Myocardial calcium (Ca) concentrations were determined using atomic absorption spectrophotometry. Approximately 0.3 gm of myocardial tissue was homogenized with lanthanum chloride and hydrochloride solution to avoid interference by protein or anions. The supernatant obtained from homogenates centrifuged for 15 minutes at 10,000 rpm was used for measurement of Ca 2ϩ with the 422.7 nm line of a Ca hollow-cathode lamp
Fig. 1. Experimental protocol:
A time line is given for the study as conducted in each heart. After 5 minutes of Langendorff perfusion (L-P) with normal modified Krebs-Henseleit bicarbonate buffer (KHB), baseline myocardial functions were carried out. After this, L-P with drugs buffered in KHB was established for a total of 10 minutes and then the heart was replaced for 30 minutes of normothermic global ischemia and reperfused with normal KHB for 30 minutes. Biopsy specimens for cGMP and calcium were taken at the baseline point, 30 minutes after ischemia, 10 minutes after reperfusion, and 30 minutes after reperfusion. In addition, separate hearts were perfused for 45 minutes with 50 ml KHB containing 20 Ci of [ 3 H] myo-inositol for the measurements of inositol-1,4,5-monophosphate. In the C group no drug was used, whereas the L group had L-arginine administered for 10 minutes before ischemia.
(n ϭ 48; six rat hearts were used at each time of each group. All hearts were also used at the measurement of cGMP)
Measurement of cGMP. Cyclic GMP was measured in the heart by a radioimmunoassay. Tissue samples were taken at the same times as for Ca measurements and immediately frozen in liquid nitrogen. The samples were homogenized in 0.1 ml of a 0.1 N HCl-10 mmol/L ethylenediaminetetraacetic acid solution and then immersed in boiling water for 3 minutes to provide an acid extract suitable for measurements of cGMP concentration. One hundred microliters of sample (either a cGMP standard or a test solution) was added to 100 L of a dioxane-triethylamine mixture containing succinic anhydride. After 10 minutes at room temperature, the reaction mixture was added to 0.5 to 1.0 ml of 0.5 mmol/L imidazole buffer containing 0.5% bovine serum albumin, 8 mmol/L theophylline, and 0.001% streptomycin. The above mixture (100 l) was added to 100 l of [ 125 I]SCAMPTME (15,000 to 20,000 cpm in an amount less than 104 mol) and 100 l of the diluted antisera. The mixture was kept at 4°C overnight (about 15 hours). A cold solution of dextran-coated charcoal (0.5 ml) was added to the above mixture and cooled in an ice-cold water bath. The charcoal was then spun down, and 0.5 ml of the supernatant was counted for radioactivity in a gamma spectrometer (n ϭ 48).
Measurement of phosphatidylinositols. Separate hearts were processed to measure inositol-1,4,5-monophosphate content. After stabilization, they were perfused for 45 minutes with 50 ml mKHB buffer containing 20 Ci of [3H] myo-inositol, and then perfused with mKHB buffer containing 10 mmol/L LiCl to inhibit inositol phosphate phosphatase. They then were randomly assigned either the C group or A group. At the same times as for calcium measurements, the left ventricle was excised from the heart and rapidly frozen in liquid nitrogen. For measurement of [3H] inositol triphosphate, the frozen tissue was homogenized with 5% perchloric acid with a Polytron homogenizer (Brinkmann Instruments, Inc., Westbury, N.Y.) and centrifuged at 8000 for 10 minutes. The supernatant was neutralized with 5 mmol/L K 2 CO 3 , and the precipitate was removed by centrifugation at 1000g for 5 minutes. The supernatant was applied to the anion exchange column. The 1 ml fractions eluted from the column were counted in duplicate for radioactivity 21 (n ϭ 48; six hearts were used at each time in each group).
Statistical analysis. Results are expressed as mean Ϯ standard error of the mean for the number of observations. Data were analyzed by analysis of variance (ANOVA)-factorial for differences between the groups using Scheffe's test, and by ANOVA-repeated measurements for accounting for potential changes between the different points of time throughout the experimental protocol within the group by using Scheffe's test. ANOVA-repeated measurements were applied to each parameter for examining both entire measuring points (data from the preischemic baseline to the end of reperfusion) and points after reperfusion. Sequential changes in each parameter also were examined by paired t test in each group. A level of p Ͻ 0.05 was accepted as being statistically significant.
Results

Hemodynamics.
No episodes of ventricular arrhythmia occurred after reperfusion in either group. Left ventricular functional data for the two groups at baseline before entering the group protocols and after 10 or 30 minutes of reperfusion are displayed in Table I .
In the group pretreated with L-arginine, dp max and LV dp/dt max were significantly higher than in the control group after 10 and 30 minutes of reperfusion. No significant differences in heart rate were noted between the L-arginine-pretreated group and the control group.
In the C group but not the A group, coronary flow was significantly reduced at 30 minutes of reperfusion compared with the preischemic values.
Tissue cGMP content (Fig. 2) . After 30 minutes of ischemia and reperfusion, cGMP content was significantly increased in the L-arginine-pretreated group (base: 1.06 Ϯ 0.12, I30: 1.94 Ϯ 0.09, R10: 1.88 Ϯ 0.14, R30: 1.55 Ϯ 0.10 pmol/mg protein), compared with the C group (base: 1.04 Ϯ 0.14, I30: Fig. 3 ). In the control group, IP3 was significantly increased after Ca 2؉ content (Fig. 4) . In both groups, Ca 2ϩ content was significantly increased after 30 minutes of ischemia compared with preischemic values, with no differences between two groups. After reperfusion, however, Ca 2ϩ content significantly increased in the control group (base: 1.46 Ϯ 0.109, I30; 4.12 Ϯ 0.164, R10: 5.11 Ϯ 0.314, R30: 6.86 Ϯ 0.544 mmol/gm dry weight, p ϭ 0.02). In the L-arginine-pretreated group, no significant change in Ca 2ϩ was noted after reperfusion (base: 1.46 Ϯ 0.109, I30: 3.72 Ϯ 0.214, R10: 3.68 Ϯ 0.158, R30: 3.14 Ϯ 0.428 mmol/gm dry weight, p ϭ 0.01).
Discussion
Previous studies have suggested that NO protects against ischemia-reperfusion injury, and cardioprotective mechanisms may be due to coronary vasodilatation, inhibition of neutrophil adherence, inhibition of platelet aggregation, protection of coronary endothelial cell function, and neutralization of free radicals. Other studies, reporting detrimental effects of NO on hearts in reperfusion 2, 3, 22 have suggested that NO inhibits mitochondrial function and produces peroxynitrite. Taken together, these results Fig. 2 . Cyclic GMP content. cyclic GMP (cGMP) contents in the myocardium were measured by radioimmunoassay at baseline (Base), after 30 minutes of ischemia (I30), after 10 minutes reperfusion (R10), and after 30 minutes reperfusion (R30). In the L group, cGMP contents were significantly higher than the C group after ischemia and reperfusion. *p ϭ 0.02, C group versus L group; #p ϭ 0.01 compared with the values of baseline. suggest that NO has opposing effects, both beneficial and detrimental, on myocardium and coronary endothelium in this situation.
Because NO has the detrimental effects of the ischemia-reperfusion myocardial injury, the concentration of L-arginine and the timing of L-arginine infusion have been difficult problems. In our experiment the infusion of higher than 3 mmol/L Larginine caused the inhibition of cardiac function (result was not shown). Engelman and colleagues 23 reported that the different timing of L-arginine infusion led the detrimental effects of cardioprotection. They reported that preischemic infusion of L-arginine reduced reperfusion injury, but L-arginine infusion during reperfusion did not lead to a cardioprotective effect. Matheis and colleagues 22 reported that administration of the NO synthase inhibitor to the extracorporeal circuit afforded protection against myocardial reoxygenation injury. The extreme release of NO on the reperfusion or reoxygenation phase may stimulate some cytotoxic oxygen radical production and promotes the reperfusion injury.
Given the complexity of these results, we speculated that NO may have different effects on the myocardium in the ischemic phase and the reperfusion phase. 23 In this study we investigated how preischemic increase of NO influences the cardioprotection on the reperfusion phase, especially regarding any association between NO and Ca 2ϩ overload.
Although Ca 2ϩ is important in cell metabolism as a second messenger, extreme accumulations in the cytosol cause cell injury. Such accumulation in hearts during ischemia-reperfusion is known as Ca 2ϩ overload, which contributes to reperfusion injury, including myocardial stunning. Ca 2ϩ overload is caused by failure of three regulatory systems of cytosolic Ca 2ϩ content: the cell membrane, through which Ca 2ϩ normally cannot pass; Ca 2ϩ pumps and channels related to the membrane; and mechanisms sequestering intracellular Ca 2ϩ stores. Previous investigators have found that inhibition of Ca 2ϩ overload with various calcium channel blockers reduces reperfusion injury. The sarcoplasmic reticulum also is critical to regulation of intracellular Ca 2ϩ stores 24 and release of calcium from the sarcoplasmic reticulum is mediated by IP3. In this study we observed that IP3 increased after 10 and 30 minutes of reperfusion compared with preischemic values, as did Ca. The relationship between IP3 and Ca in our results suggests that increased IP3 induced more Ca accumulation, resulting in reperfusion injury. [25] [26] [27] [28] We now consider the mechanism by which NO reduces IP3 after reperfusion. As an intracellular messenger, NO activates sGC, which causes an increase in cGMP concentration. The diverse biologic effects of cGMP include relaxation of vascular smooth muscle, inhibition of platelet aggregation, and regulation of phosphodiesterase and protein kinase. Clementi and coworkers 29 reported that in neural cells NO appeared to modulate inositol phosphate generation and Ca 2ϩ release primarily at the level of phospholipase C, mediated by cGMPdependent protein kinase I. Evans and colleagues 30 have demonstrated that increasing the level of cGMP in the myocardium inhibited both positive inotropic and phosphatidylinositol responses to ␣ 1 -stimulation in isolated preparations of papillary muscle. Hirata and coworkers 5 investigated the mechanism of cGMP inhibition of inositol phosphate formation in rat aorta, and Nakashima and coworkers 6 reported cGMP inhibition of polyphosphoinositide hydrolysis in human platelets. Our data show that cGMP accumulation is significantly higher in the L-arginine-pretreatment group than in the control group after reperfusion, and it was thought that accumulated cGMP in the treated group inhibited the increase of IP3 and Ca 2ϩ in the similar mechanism, followed by significantly better cardioprotection.
Previous studies have demonstrated cardioprotective mechanisms of NO caused by coronary vasodilatation. However, our results demonstrate other mechanisms. These data in our study indicate that the cardioprotective effect of L-arginine pretreatment may be due to the inhibition of calcium overload by means of cGMP.
Because NO has various effects including peroxynitrite production, further preclinical studies are necessary to refine dosage and timing of the NO precursor pretreatment protocol. 23 
